Ignite Creation Date:
2024-10-25 @ 7:54 PM
Last Modification Date:
2024-10-26 @ 3:43 PM
Study NCT ID:
NCT06646588
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-10-07
Brief Title:
Fruquintinib in Combination With Tislelizumab Followed by Radiotherapy in Esophageal Squamous Cell Carcinoma
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Fruquintinib in Combination With Tislelizumab Followed by Radiotherapy in Relapsed or Progressive Esophageal Squamous Cell Carcinoma
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
SJZ-RMEEC01
Brief Summary:
According to the Global Burden of Disease Study the number of esophageal cancer cases globally increased from 319969 in 1990 to 534563 in 2019 a relative increase of 6707 per cent In addition GLOBOCAN 2020 reported that the global incidence of esophageal cancer climbed to 604100 accounting for 31 of all tumor sites and ranking 7th out of 36 cancers In addition the number of global deaths from esophageal cancer increased from 319332 in 1990 to 498067 in 2019 a relative increase of 5597GLOBOCAN 2020 reported about 544076 new esophageal cancer deaths which accounted for 55 of all study centres and ranked 6th among 36 cancers Chemotherapy is the standard of care for advanced esophageal squamous cell carcinoma but conventional chemotherapy has limited efficacy and studies have shown lower median overall survival with chemotherapy in patients with advanced esophageal cancer compared to patients with other stages In recent years with the first-line approval of immune checkpoint inhibitors the treatment of esophageal cancer has entered the immune era Immune checkpoint inhibitors have become an important therapeutic option for patients with advanced esophageal cancer who have failed chemotherapy This study will explore the efficacy and safety of this small molecule anti-angiogenic drug fruquintinib in combination with tislelizumab in esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None